Pharmamarketeer
onderzoekwet- en regelgeving

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

21 februari 2019
InPharm.com

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, its investigational CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid leukaemia and other CD123-expressing hematologic malignancies after the deaths of two patients which are considered to be “at least possibly related” to the use of the drug.

The deaths were originally detailed in a safety report submitted by Xencor to the FDA.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)